The additional data is from mouse testing. It's always possible that anima data may not translate into results for humans, but we have some human phase data that correlates already with a lot of what they are seeing. Without digging too deep into what if's, the data is great. I guess the question always in the back of my mind, is what are the downstream effects of these huge lipid reductions this accomplishes... like are their possible unforeseeable downstream effects. Will this be the holy grail of lipid lowering agents, or a drug that is used in small doses at periodic intervals to decompress the effects in people with serious glycogen storage diseases. That's the real question. And I don't think we may actually know the answer to that until phase 3 or later. The longer we go without unexpected weird side effects divulged, the higher the chances get that it may be closer to being a great all around lipid lowering agent, that could be a miracle drug in a different dose range for those poor individuals suffering from GSD. Time will tell. 5 weeks until possible sarm data... things should starting heating up over the next 2 weeks... let's hope.
News 
Market Data 
Discover 
